What does this research mean for the field?

Amivantamab demonstrates significant antitumor activity, achieving a 42% objective response rate, and a manageable safety profile in patients with recurrent/metastatic head and neck squamous cell carcinoma previously treated with checkpoint inhibitors and chemotherapy. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The study aimed to evaluate the effectiveness of amivantamab in recurrent/metastatic head and neck squamous cell cancer after prior treatments.

June 2, 2026Open Access

Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 study

Key Points

The study aimed to evaluate the effectiveness of amivantamab in recurrent/metastatic head and neck squamous cell cancer after prior treatments.
Cohort 1 of OrigAMI-4 (NCT06385080) administered amivantamab subcutaneously every three weeks to 102 participants.
Primary endpoint was objective response rate (ORR) assessed by independent review; secondary endpoints included PFS and OS.
Participants had prior exposure to PD-(L)1 inhibitors and platinum-based chemotherapy, excluding those previously treated with anti-EGFR.
Blinded review assessed ORR was 42% (95% CI, 32-52) with a complete response rate of 15%.
Median PFS was 6.8 months (95% CI, 5.2-8.3) and median OS was 12.5 months (95% CI, 10.2-16.8).
Investigator-assessed ORR was 47% (95% CI, 37-57) and adverse events were consistent with prior knowledge.

Abstract

Single-agent paclitaxel or cetuximab after immune checkpoint inhibitor (ICI) and chemotherapy demonstrated objective response rates (ORRs) of 21%-24% in recurrent/metastatic (R/M) head/neck squamous cell cancer (HNSCC). EGFR and MET are overexpressed in R/M HNSCC. Amivantamab, an EGFR-MET bispecific antibody, may be a rational treatment. Cohort 1 of OrigAMI-4 (NCT06385080) evaluated subcutaneous amivantamab administered every three weeks in participants with R/M HNSCC after PD-(L)1 inhibitor and platinum-based chemotherapy. Prior anti-EGFR was exclusionary. The primary endpoint was RECIST v1.1 ORR. Secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. In 102 participants, blinded independent central review-assessed ORR was 42% (95% CI, 32-52); the complete response rate was 15%. Median DoR was not reached (NR; 95% CI, 6.9-NR); 56% of responses lasted ≥6 months. Investigator-assessed ORR was 47% (95% CI, 37-57). At a median follow-up of 11.8 months (range, 1.1-21.9), median PFS and OS were 6.8 months (95% CI, 5.2-8.3) and 12.5 months (95% CI, 10.2-16.8), respectively. Adverse events were consistent with previous experience with no new safety signals. Treatment-related discontinuations were low (8%). Amivantamab demonstrated greater antitumor activity in participants previously exposed to ICI and chemotherapy than what has been reported for paclitaxel or cetuximab.

Read Full Paperexternally

AI에게 질문

Bookmark

View Full Paper